Also known as Cagrilintide/semaglutide · cagrilintide + semaglutide
Novo Nordisk’s fixed once-weekly combination of cagrilintide (amylin) + semaglutide (GLP-1) — 20.4%–22.7% mean weight loss in Phase 3, filed with the FDA in December 2025.
Research refreshed
CagriSema is not a single molecule but a fixed-dose combination of two peptides already in this catalog: cagrilintide, a long-acting amylin analog, and semaglutide, the GLP-1 agonist. Novo Nordisk pairs two distinct satiety pathways in one once-weekly injection. The Phase 3 REDEFINE program reported 20.4%–22.7% mean weight reduction at 68 weeks (NEJM 2025), and Novo filed for FDA approval in December 2025, with a decision expected in 2026.
CagriSema is a combination product, and that is the whole point of it. Rather than engineer a single peptide that hits several receptors — the multi-agonist route taken by tirzepatide and retatrutide — Novo Nordisk co-formulates two of its existing peptides: the amylin analog cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite, but through different receptor systems (amylin/calcitonin complexes versus the GLP-1 receptor), so combining them is studied for additive weight effect from a single weekly injection.
The Phase 3 REDEFINE program delivered the largest data package ever assembled for a combination obesity therapy. REDEFINE-1 (Garvey et al., NEJM 2025, NCT05567796) reported 20.4% mean weight reduction at 68 weeks regardless of adherence — 22.7% among participants who stayed on treatment — versus 3.0% on placebo, with 40.4% of adherent participants losing ≥25% of body weight and 23.1% losing ≥30%. REDEFINE-2 (NEJM 2025), in adults with overweight/obesity and type 2 diabetes, reported −13.7% versus −3.4% placebo. REDEFINE-3, a cardiovascular-outcomes trial, is ongoing.
Because it is a co-formulation, CagriSema has no molecular formula or sequence of its own — its properties are those of its two components, each documented on its own monograph here. Novo Nordisk submitted the FDA application in December 2025 — the first once-weekly GLP-1/amylin combination to reach filing — with a decision anticipated in 2026. It is not yet approved anywhere.
Co-agonism across two complementary satiety systems: semaglutide activates the GLP-1 receptor while cagrilintide activates amylin and calcitonin receptor complexes — additive appetite suppression and slowed gastric emptying from one weekly injection.
Behind every vial of CagriSema is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how CagriSema, specifically, is brought into being.
CagriSema begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
CagriSema is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — CagriSema plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of CagriSema proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of CagriSema — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
CagriSema is a co-formulation, not a synthesized molecule: it is manufactured by making its two component peptides — cagrilintide and semaglutide — separately, each to its own spec and certificate of analysis, and combining them at fixed doses. Its quality therefore rests on the identity and purity of two peptides at once, described on their individual monographs.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning CagriSema, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
CagriSema is Novo Nordisk’s fixed once-weekly combination of two peptides — cagrilintide (an amylin analog) and semaglutide (a GLP-1 agonist) — for weight management. Phase 3 reported 20.4%–22.7% mean weight reduction at 68 weeks; it was filed with the FDA in December 2025.
REDEFINE-1 (NEJM 2025): 20.4% mean at 68 weeks regardless of adherence, 22.7% among those who stayed on treatment, versus 3.0% placebo. About 40% of adherent participants lost ≥25% of body weight and 23% lost ≥30%. REDEFINE-2 (with type 2 diabetes): 13.7% versus 3.4%. Trial means, not individual predictions.
No — it is a co-formulation of two separate peptides (cagrilintide and semaglutide), each with its own monograph here, so it has no single molecular formula or sequence.
Tirzepatide is one molecule hitting two receptors (GIP + GLP-1, ~22.5% mean weight loss in SURMOUNT-1); retatrutide is one molecule hitting three (adds glucagon, ~28.7% in its first Phase 3 readout). CagriSema reaches a similar range by combining two molecules (GLP-1 + amylin) instead. None of these trials is head-to-head.
In REDEFINE trials the most common adverse events were gastrointestinal — nausea, vomiting, diarrhea, constipation — mostly during dose escalation and mostly mild to moderate, consistent with both component classes. This page is a research reference, not medical advice.
Novo Nordisk filed the FDA application in December 2025 — the first once-weekly GLP-1/amylin combination to reach filing — with a decision anticipated in 2026. It is not approved anywhere today; anything sold as CagriSema now is outside any regulated channel.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
ViewThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.